All In Biotech

Drug Trial Radar · NCT06891443

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

A Double-Masked, Randomized, Placebo-Controlled, Paired-Eye Study to Evaluate the Efficacy, Safety and Tolerability of Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Due to the c.2991+1655A>G (p.Cys998X) Mutation in the CEP290 Gene

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jun 4, 2025

Primary completion

Nov 2027

Study completion Oct 2028

Sponsor

Lead sponsor
Laboratoires TheaIndustry
Sponsor type
Industry
Collaborators
Sepul Bio
First posted
Mar 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A\>G (p.Cys998X) mutation in the CEP290.

Conditions

  • Leber Congenital Amaurosis 10
  • Blindness
  • Leber Congenital Amaurosis
  • Sensation Disorders
  • Vision Disorder
  • Neurological Manifestations
  • Eye Diseases, Hereditary
  • Eye Diseases
  • Eye Disorders Congenital
  • Retinal Disease

Interventions

  • sepofarsenDrug

    RNA antisense oligonucleotide for intravitreal injection

  • Placebo IVTOther

    Placebo with identical appearance to sepofarsen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Best-Corrected Visual Acuity (BCVA)Time frame: 12 Months

Locations

18 sites in 10 countries. Site status is shown where the registry gives one.

  • UCSF Wayne and Gladys Valley Center for Vision

    San Francisco, California · Recruiting

  • University of Miami - Bascom Palmer Eye Institute

    Miami, Florida · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • University of Minnesota Medical School

    Minneapolis, Minnesota · Withdrawn

  • University of Pennsylvania - Center for Advanced Retinal & Ocular Therapeutics

    Philadelphia, Pennsylvania · Recruiting

  • Sydney Eye Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Universitair Ziekenhuis Gent (UZ)

    Ghent, Belgium · Recruiting

  • INRET Clínica/ Santa Casa de Misericórdia de Belo Horizonte

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Federal University of São Paulo - Hospital São Paulo (UNIFESP-HSP)

    São Paulo, São Paulo, Brazil · Recruiting

  • University of Alberta

    Edmonton, Alberta, Canada · Recruiting

  • The Hospital for Sick Children - SickKids

    Toronto, Ontario, Canada · Recruiting

  • Centre de maladies rares CHNO des Quinze Vingt

    Paris, France · Recruiting

  • Justus-Liebig Universität - Department of Ophthalmology

    Giessen, Germany · Recruiting

  • Klinikum der Ludwig-Maximilian Universität München

    München, Germany · Recruiting

  • University of Tuebingen - Inst. for Ophthalmic Research

    Tübingen, Germany · Recruiting

  • Radboud Universitair Medisch Centrum

    Nijmegen, Netherlands · Recruiting

  • Hospital Sant Joan de Déu (SJD Barcelona Children's Hospital)

    Barcelona, Spain · Recruiting

  • Moorfields Eye Hospital NHS Foundation Trust

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.